IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE AT NASHVILLE

TERRY LYNN KING,)
Plaintiff,) <u>CAPITAL CASE</u>
v.) Case No. 3:18-cv-01234
LISA HELTON, et al.,) JUDGE CAMPBELL
Defendants.)
DONALD MIDDLEBROOKS,)
Plaintiff,) CAPITAL CASE
v.) Case No. 3:19-cv-01139
LISA HELTON, et al.,) JUDGE CAMPBELL
Defendants.)

NOTICE OF CORRECTIONS OF INACCURACIES AND/OR MISSTATEMENTS

Counsel for Defendants submit this filing to correct inaccuracies and/or misstatements in Defendants' filings in *King* and *Middlebrooks*.

Tennessee death row inmate Oscar Smith was scheduled to be executed on April 21, 2022. On the date of his scheduled execution, Counsel for Defendants were notified by Defendants that certain lethal injection chemicals may not have been tested in accordance with the lethal injection protocol. (Exhibit 1 at 19-20.) Thereafter, Governor Lee issued Oscar Smith a reprieve from execution of the sentence of death. (*Id.* at 18-19). On May 2, 2022, Governor Lee issued a press release stating that the lethal injection chemicals to be used in the April 21, 2022 execution of death row inmate Oscar Smith were tested for "potency and sterility but not endotoxins." (Press

Release, Office of the Governor, Gov. Lee Calls for Independent Review Following Smith Reprieve (tn.gov) (May 2, 2022) (attached as Exhibit 2).) As a result, Governor Lee directed former U.S. Attorney Ed Stanton to conduct an independent investigation of the following:

- Circumstances that led to testing the lethal injection chemicals for only potency and sterility but not endotoxins preparing for the April 21 execution
- Clarity of the lethal injection process manual that was last updated in 2018, and adherence to testing policies since the update
- [TDOC] staffing considerations

(*Id*.)

As a result of the circumstances leading to Governor Lee's reprieve of Mr. Smith's execution, undersigned counsel filed a Notice of Inaccuracies or Misstatements to Be Corrected upon information and belief that filings made by counsel on behalf of Defendants contained inaccuracies or misstatements on May 6, 2022. (King, D.E. 217; Middlebrooks, D.E. 58.) And because of undersigned counsel's belief that filings may have contained inaccuracies or misstatements, counsel moved to withdraw its motion for summary judgment in the King case. (King, D.E. 218.)

Mr. Stanton's investigation was completed with the issuance of the Report and Findings of the Tennessee Lethal Injection Protocol Investigation on December 13, 2022. ("Report," Exhibit 1.) Counsel for Defendants have conducted a good faith review of Defendants' filings in King and Middlebrooks to identify the existence of any known misstatements and inaccuracies contained therein in light of the report's findings. Counsel for Defendants are prepared to make further corrections should this become necessary.¹

¹ Counsel for Defendants are also aware of the finding in the report that "On April 22, 2022, the Tennessee Attorney General's Office received 31 pages of testing results dating back to 2018,

Counsel for Defendants present the following information to correct known inaccuracies and/or misstatements in the King filings:

Docket Entry	PageID#	Inaccuracy/Misstatement	Correction
27 – Defs' Response Opp. Pl. Miller's Mot. Temporary Restraining Order	1775	"Defendants will be prepared and able to carry out [Mr. David] Miller's death sentence by lethal injection according to the Lethal Injection Procedures"	The compounded midazolam yielded a below range potency and was not tested for endotoxins. (Exhibit 1 at 26-27.) The midazolam was not used as Mr. Miller ultimately elected to be executed by electrocution. (<i>Id.</i>)
33 – Defs' Response Opp. Pl. Miller's Mot. Disclosure of Information	1913	"In light of these attestations, Miller's protest that there is 'no proof' that the Defendants can carry out a lethal injection as required under the protocol is baseless."	The compounded midazolam yielded a below range potency and was not tested for endotoxins. (Exhibit 1 at 26-27.) The midazolam was not used as Mr. Miller ultimately elected to be executed by electrocution. (<i>Id.</i>)
33 – Defs' Response Opp. Pl. Miller's Mot. Disclosure of Information	1913	"Miller's claim that both "recent executions [of Mr. Billy Irick and Mr. Edmund Zagorski] deviated from the execution protocols," is merely speculative." (citation omitted)	The executions of Mr. Billy Irick and Mr. Edmund Zagorski deviated from the Protocol because the midazolam used in the execution of Mr. Irick was not tested for endotoxins and potency and the compounded lethal injection chemicals prepared for Mr. Zagorski's execution were not tested for endotoxins and failed potency testing. (Exhibit 1 at 1-2.)
136 – Joint Discovery Dispute Statement	5210	"Discovery not relevant and proportional to Plaintiff's facial challenge includes discovery to answer hypothetical questions about how the protocol's implementation could fail when it has not so far."	To the extent that this statement could be read as asserting that the Protocol's implementation has not failed, in the application of the July 5, 2018

although only 17 of those had been produced previously in litigation." (Exhibit 1 at 20.) Defendants are in the process of repeating all collection efforts with the assistance of a vendor.

Docket Entry	PageID#	Inaccuracy/Misstatement	Correction
183 – Mem. Supp. Defs' Mot. Summary J.	5676	"The Pharmacist also arranges third-party testing of the compounded drugs to ensure their potency and sterility."	In the application of the July 5, 2018 Protocol, the compounded lethal injection chemicals have not been tested for endotoxins and the midazolam used in Mr. Billy Irick's execution was not tested for potency. (Exhibit 1 at 1-2, 12-13, 17-33.)
184 — Defs' Statement Undisputed Material Facts	5730 ¶ 211	"The Compounding Pharmacist arranges for an independent third-party laboratory to test the compounded LIC for potency, sterility, and endotoxins."	In the application of the July 5, 2018 Protocol, the compounded lethal injection chemicals have not been tested for endotoxins and the midazolam used in Mr. Billy Irick's execution was not tested for potency. (Exhibit 1 at 1-2, 12-13, 17-33.)
184 – Defs' Statement Undisputed Material Facts	5730 ¶ 212	"The Pharmacy ships the compounded LIC to TDOC within 24 to 48 hours of receiving the results of the testing from the independent third party."	Text messages between the Drug Procurer and the Pharmacy Owner indicate that, at TDOC's urging, the Pharmacy Owner shipped the midazolam to TDOC before receiving the sterility test results for the midazolam used in the execution of Mr. Billy Irick. (Exhibit 1 at 24.) Text messages between the Drug Procurer and the Pharmacy Owner indicate that, at TDOC's urging, the Pharmacy Owner shipped the midazolam to TDOC before receiving the sterility test results for the midazolam intended for use in the execution of Mr. Edmund Zagorski. (Exhibit 1 at 25.) Text messages between the Drug Procurer and the Pharmacy Owner also indicate that the Pharmacy Owner shipped the midazolam to TDOC before receiving the sterility test results for the midazolam used in the

Docket Entry	PageID#	Inaccuracy/Misstatement	Correction
			execution of Mr. Donnie Johnson. (Exhibit 1 at 27.)
			It appears that the Pharmacy Owner may have shipped the potassium chloride intended for use in the execution of Mr. Stephen West to TDOC before receiving the potency test results. (Exhibit 1 at 30.)
			It appears that the Pharmacy Owner may have shipped the midazolam and potassium chloride intended for use in the execution of Mr. Lee Hall to TDOC before receiving the potency and sterility test results for either chemical. (Exhibit 1 at 31-32.)
208 – Defs' Resp. Opposition Pl's Mot. Deny or Defer Consideration Defs' Mot. Summary J.	12694	"[A]ll the essential facts are in the record "	In the application of the July 5, 2018 Protocol, the compounded lethal injection chemicals have not been tested for endotoxins and the midazolam used in Mr. Billy Irick's execution was not tested for potency. (Exhibit 1 at 1-2, 12-13, 17-33.)

Counsel for Defendants present the following information to correct known inaccuracies and/or misstatements in the Middlebrooks filings:

Docket	PageID#	Inaccuracy/Misstatement	Correction
Entry			
53 – Defs'	507 ¶ 102	"102. Defendants followed the	Defendants failed to comply with the
Answer		July 5, 2018 midazolam-based	Protocol's requirements regarding
to First		lethal injection protocol in	testing for endotoxins. (Exhibit 1 at
Amended		carrying out Donnie Johnson's	2, 12-13, 22, 27-28.)
Compl.		execution.	
		ANSWER: Admit"	

Respectfully submitted,

JONATHAN SKRMETTI Attorney General and Reporter

s/ Scott C. Sutherland SCOTT C. SUTHERLAND (29013) Deputy Attorney General

DEAN ATYIA (039683) MIRANDA JONES (36070) CODY N. BRANDON (037504) JOHN R. GLOVER (037772) Assistant Attorneys General Law Enforcement and Special Prosecutions Div. P.O. Box 20207 Nashville, Tennessee 37202-0207 Off. (615) 532-7688 Fax (615) 532-4892 Scott.Sutherland@ag.tn.gov Dean.Atyia@ag.tn.gov Miranda.Jones@ag.tn.gov Cody.Brandon@ag.tn.gov John.Glover@ag.tn.gov Counsel for Defendants

CERTIFICATE OF SERVICE

I certify that on May 1, 2023, a copy of the foregoing was filed and served via the Court's

CM/ECF system on the following counsel for *Middlebrooks*:

Amy Harwell Houston Goddard Katherine Dix Katheryn Thomas Kelley Henry Marshall Jensen Richard Tennent Federal Public Defender's Office (MDTN)

615-695-6906 Amy Harwell@fd.org houston goddard@fd.org Katherine Dix@fd.org kit thomas@fd.org Kelley Henry@fd.org

Marshall Jensen@fd.org Richard Tennent@fd.org

Nashville, TN 37203

810 Broadway, Suite 200,

And on the following counsel for *King*:

Alex Kursman Lynne Leonard Anastassia Baldridge Hayden Nelson-Major **Assistant Federal Defenders** Federal Community Defender for the E.D. Penn. Suite 545 West, The Curtis 601 Walnut St. Philadelphia, PA 19106 (215) 928-0520 alex kursman@fd.org lynne leonard@fd.org ana baldridge@fd.org

David Esquivel Sarah Miller Jeremy Gunn Michael Tackeff

hayden nelson-major@fd.org

Bass, Berry & Sims 150 Third Ave. South Nashville, TN 37201 (615) 742-6200 desquivel@bassberry.com smiller@bassberry.com jeremy.gunn@bassberry.com michael.tackeff@bassberrv.com

Alice Haston Amy Rao Mohan Christopher C. Sabis Sherrard Roe Voight & Harbison, PLC 150 Third Ave. South **Suite 1100** Nashville, TN 37201 (615) 742-4539 ahaston@srvhlaw.com amohan@srvhlaw.com csabis@srvhlaw.com

> s/ Scott C. Sutherland SCOTT C. SUTHERLAND